Pfizer

Pfizer Gets Support For Arthritis Drug Approval

Pfizer Inc. (NYSE:PFE) has moved one step closer to approval of a drug that will improve options in the treatment of Rheumatoid Arthritis. An advisory panel specializing in arthritis medication voted 8-2 in favor of the drug stating that it's benefits outweighed its potential risks. The support of the committee brings the company one step closer to approval of the drug, which could be a boon to the company's future sales.

The medication . . .

SORRY!

This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible


Saved Articles
X
TextTExtLInkTextTExtLInk

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers


0